

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA of nintedanib for treating idiopathic pulmonary  
fibrosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At the scoping workshop 1 consultee was concerned that trial data was only available for people of 40 years and older and therefore would exclude people below this age. The Chair explained that NICE does not discriminate against age and that this was not an equality or diversity issue which needed to be addressed in the scope.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No issues relating to equality have been included in the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified so no changes to the matrix were needed.

**Approved by Associate Director (name):** Helen Knight

**Date:** 25/02/2015